Loading organizations...
§ Private Profile · London, England, United Kingdom
Precision medicine technologies developer creating AI-driven personalized treatments for patients, focused on hypertension.
Closed Loop Medicine is a London, UK-based healthcare technology company that develops precision medicine software to tailor treatments and optimize personalized dosing for individual patients using artificial intelligence. The organization focuses on specific clinical applications such as hypertension management, utilizing data-driven approaches to improve therapeutic outcomes and reduce adverse drug reactions for patients. To support its ongoing clinical programs and proprietary platform development, the enterprise has raised over $37 million in total venture capital funding, which includes a £2.1 million pre-Series A financing round. The company has secured strategic financial grants from InnovateUK and recently appointed experienced healthcare executive Luba Greenwood as its Non-Executive Chair to guide its international commercial expansion strategy. Closed Loop Medicine was originally founded in 2017 by Hakim Yadi and Paul Goldsmith at the Babraham Institute located in Cambridge, United Kingdom.
Closed Loop Medicine has raised $38.8M across 4 funding rounds.
Closed Loop Medicine has raised $38.8M in total across 4 funding rounds.
Closed Loop Medicine has raised $38.8M across 4 funding rounds. Most recently, it raised $17.8M Series A in November 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 3, 2021 | $17.8M Series A | Lennart Hergel, TIM REA | Cambridge Angels, Matt Pierce, IQ Capital, Clare Terlouw, Longwall Ventures, Meltwind | Announced |
| Nov 1, 2021 | $18M Seed | — | Amadeus Capital Partners, Ananda Impact Ventures, Business Growth Fund, Downing Ventures, Parkwalk Advisors, Jonathan Milner | Announced |
| Jul 24, 2020 | $320K Grant | Innovate UK | — | Announced |
| May 9, 2019 | $2.7M Seed Plus | — | Sherry Coutu, ED Stacey, Rebecca Todd, Martlet Capital | Announced |
Closed Loop Medicine has raised $38.8M in total across 4 funding rounds.
Closed Loop Medicine's investors include Lennart Hergel, Tim Rea, Cambridge Angels, Matt Pierce, IQ Capital, Clare Terlouw, Longwall Ventures, Meltwind, Amadeus Capital Partners, Ananda Impact Ventures, Business Growth Fund, Downing Ventures.
Closed Loop Medicine is a HealthTech company founded in 2017 that develops prescription combination products integrating drugs, software, and devices to enable personalized medicine, particularly for chronic conditions like hypertension and insomnia[1][2][3]. It builds products such as CLM-HT01 for hypertension and CLM-IN01 for insomnia, serving patients, clinicians, pharmaceutical companies, payors, and healthcare providers by solving the limitations of one-size-fits-all dosing, which leads to suboptimal outcomes, higher costs, and adverse reactions[1][2][3]. The proprietary platform optimizes drug dosing through patient data from wearables and apps, delivering tailored care that improves efficacy, reduces side effects, and lowers healthcare costs, with $20.58M raised and positive clinical results announced as recently as 2024[2][3].
Closed Loop Medicine was incorporated on January 26, 2017, in the UK (initially as Closed Loop Pharma Ltd., renamed shortly after) by founder Paul Goldsmith, who brings expertise in healthcare innovation[3][4][5]. Headquartered in Cambridge at Babraham Research Campus, the idea emerged from recognizing flaws in traditional healthcare models—struggling with chronic disease management due to generic dosing—and the need for "closed loop" systems combining therapeutics, digital tools, and devices for patient-centric care[1][2][3]. Early traction included incubator/accelerator support, partnerships like with CPI and Queen Mary University London, and clinical advancements, such as the 2024 publication of hypertension study results in the Journal of the American Heart Association[2][3].
Closed Loop Medicine rides the personalized medicine trend, fueled by advances in wearables, AI analytics, and digital therapeutics amid rising chronic disease prevalence and healthcare cost pressures[1][2]. Timing aligns with regulatory shifts favoring combination products (drug + software as medical devices) and post-pandemic demand for remote, data-driven care, positioning it against competitors like DarioHealth and Lark Health[2][3]. Market forces—such as value-based care mandates and pharma's push for optimized therapies—favor its model, which creates new IP-protected revenue streams and influences ecosystems by partnering with providers and innovators to shift from disease-centric to individual-focused treatment[1][2].
Closed Loop Medicine is poised for expansion with its clinically validated platform, likely advancing more products beyond hypertension and insomnia into chronic diseases, leveraging recent funding and evidence to secure pharma partnerships and regulatory approvals[2][3]. Trends like AI-enhanced wearables, real-world evidence requirements, and global personalized medicine growth (projected to surge) will accelerate its trajectory, potentially evolving it into a key enabler of scalable, cost-effective care[1][2]. As healthcare systems prioritize outcomes over volume, its closed-loop innovations could redefine chronic disease management, delivering the personalized dosing promise that sparked its founding.